Aim Accurate lymph node staging is vital to inform optimum treatment decisions in patients with oesophageal cancer. This study evaluates the accuracy of contemporary Nstaging and provides radiological-pathological correlation in patients with lymph node metastases (LNMs) that were radiologically staged N0.
Introduction 4
Contemporary radiological staging of oesophageal cancer (OC) involves a multi-5 modality approach. In the UK, patients have initial contrast-enhanced computed 6 tomography (CECT) of the thorax and abdomen following histological confirmation to 7 assess the potential resectability of the tumour, or any distant metastatic disease 8 which may preclude radical therapy. 9
If the patient is deemed suitable for radical treatment, either in the form of definitive 10 chemo-radiotherapy (dCRT) or surgery (+/-neo-adjuvant therapy), positron emission 11 tomography combined with computed tomography (PET/CT) and endoscopic 12 ultrasound (EUS) are performed for a more detailed assessment of disease stage. 13
(1) PET/CT has greater sensitivity for distant metastatic disease than CECT (2) , 14 whereas EUS is regarded as the 'gold-standard' investigation for defining T-and N-15 stage, whilst also assisting surgical and radiotherapy planning. (3) 16 This staging process is complex and time-consuming but necessary, because each 17 modality has limitations for lymph node staging. CECT provides anatomical 18 information only, relies on size criteria and involves radiation. PET/CT also involves 19 radiation but provides additional functional metabolic data and improves the positive 20 predictive value (PPV) of lymph node metastases (LNMs) 
. (4) The differentiation of 21
Revised Manuscript 2 peri-tumoural LNMs from adjacent avid tumour can be challenging on PET images. 22 (5) This may increase 'false-negative' rates therefore under-staging the extent of 23 nodal disease. EUS has better sensitivity compared to CECT and PET/CT due to its 24 superior contrast resolution. 25
The prognosis of OC is poor, with 5-year survival approximately 13%. (6) Many 26 patients present with advanced disease and the incidence is increasing. (7) The 27 presence of LNMs is a major prognostic indicator, therefore it is vital to stage nodal 28 disease accurately. (8) nodes identified in the resection specimen were prepared in 3 mm slices for 119 pathological evaluation. N-stage was then assigned depending on the number of 120
LNMs identified. TRG of the primary tumour was assigned according to the degree 121 of fibrosis compared to residual tumour cells. (11) In discordant cases, all available 122 resection specimens that were radiologically staged N0 but pathologically N+ were 123 further evaluated. All available specimens were retrieved and reviewed from the 124 archive. Due to the retrospective nature of analysis, some of the older cases were 125 archived off-site, and were unavailable at the time of evaluation. The maximum size 126 (long axis) of both involved lymph nodes and metastases within those lymph nodes, 127
were retrospectively recorded. Maximum size was defined as the largest dimension 128 on the glass slide measured by a Consultant Pathologist. A micro-metastasis is 129 defined as tumour deposit measuring ≤2 mm. (15 Fifteen archived resection specimens in patients pre-operatively staged N0 were 180 available for retrospective measurement of the lymph nodes and their respective 181 metastases. In total, 50 involved lymph nodes were assessed. (Table 2) The median 182 size of involved lymph nodes was 6 mm (range 2-15 mm) and the median metastasis 183 size was 3 mm (0.5-13.5 mm). Twenty-two (44%) LNMs measured ≤2 mm, which 184 are defined as micro-metastases. (Fig. 1 ) Forty-one (82%) LNMs were ≤6 mm and 185 46 (92%) LNMs were ≤10 mm. A metastasis to lymph node size ratio was 186 calculated. Thirty-one (62%) of the lymph nodes examined were replaced with ≥50% 187 metastatic deposit, 19 (38%) were replaced with <50% metastatic deposit, with 12 188 (24%) replaced with <25% metastatic deposit, using maximum size criteria. 189 including disease evolution, greater inter-observer variability between reporters, and 233 fewer, but more specialised upper GI cancer pathologists reporting the resection 234 specimens, with possibly higher rates of LNM detection. (15) 235 Accuracy of diagnosing N+ disease with CECT, EUS and PET/CT was 54.5%, 236 55.4% and 57.1%, respectively. In a clinical context, these results are unsatisfactory 237
given that the presence of LNMs is such a major prognostic indicator. (8) The 238 sensitivity and specificity for identifying N0 vs N+ disease with CECT, EUS and 239 PET/CT was 39.7% and 77.3%, 42.6% and 75.0%, and 35.3% and 90.9%. 240
Specificity results are comparable with past meta-analyses but sensitivity results are 241 lower for all modalities. Previously published literature states sensitivity for N-242 staging of EUS, CECT and PET/CT is 80%, 50 % and 57%, and specificity is 70%, 243 83% and 85%, respectively. (2) However, this meta-analysis was conducted prior to 244 this centralisation of many upper GI cancer services. The reduced sensitivity of 245 staging investigations is supported by our results, which demonstrate that under-246 staging is more common for all modalities. 
